Structural basis of light chain amyloidogenicity: Comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vλ6 proteins

Journal of Molecular Recognition

Volumn 17, Issue 4, 2004, Pages 323-331

  Wall, Jonathan S ^a   Gupta, Vibha ^a   Wilkerson, Matthew ^a   Schell, Maria ^a   Loris, Remy ^b   Adams, Paul ^c   Solomon, Alan ^a   Stevens, Fred ^d   Dealwis, Chris ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d ARGONNE NATIONAL LABORATORY   (United States)

Author keywords

Amyloid; Fibrillogenesis; Light chains; Three dimensional structure; X ray diffraction

Indexed keywords

AMINO ACID; AMYLOID; ARGININE; ASPARAGINE; IMMUNOGLOBULIN LIGHT CHAIN; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; ELECTRICITY; GENETICS; HUMAN; HYDROPHOBICITY; IMMUNOGLOBULIN VARIABLE REGION; METABOLISM; MUTATION; PROTEIN DENATURATION; PROTEIN TERTIARY STRUCTURE; THERMODYNAMICS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; AMINO ACIDS, NEUTRAL; AMYLOID; ARGININE; ASPARAGINE; CRYSTALLOGRAPHY, X-RAY; ELECTROSTATICS; HUMANS; HYDROPHOBICITY; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MODELS, MOLECULAR; MUTATION; PROTEIN DENATURATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; THERMODYNAMICS;

EID: 3142641190     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmr.681     Document Type: Article

References (53)

1. Bellotti V, Stoppini M, Mangione PP, Fornasieri A, Min L, Merlini G, Ferri G. 1996. Structural and functional characterization of three human immunoglobulin kappa light chains with different pathological implications. Biochim. Biophys. Acta 1317(3): 161-167.
2. Bellotti V, Mangione P, Merlini G. 2000. Review: immunoglobulin light chain amyloidosis - the archetype of structural and pathogenic variability. J. Struct. Biol. 130: 280-289.
3. Bishop MF, Ferrone FA. 1984. Kinetics of nucleation-controlled polymerization. A perturbation treatment for use with a secondary pathway. Biophys. J. 46: 631-644.
4. Bosshard HR, Marti DN, Jelesarov I. 2004. Protein stabilization by salt bridges: concepts, experimental approaches and clarification of some misunderstandings. J. Mol. Recognit. 17(1): 1-16.
5. Brick P, Blow DM. 1987. Crystal structure of a deletion mutant of a tyrosyl-tRNA synthetase complexed with tyrosine. J. Mol. Biol. 194(2): 287-297.
6. Brünger AT, Adams P, Clore G, Delano W, Gros P, Gross-Kuntsleve R, Jiang J, Kuszewski J, Nilges M, Pannu N, Read R, Rice L, Simonson T, Warren G. 1998. Crystallography and NMR System: a new software suite for macromolecular structure determination. Acta Crystallogr. D 54: 905-921.
7. Chili F, Webster P, Taddei N, Clark A, Stefani M, Ramponi G, Dobson CM. 1999. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl Acad. Sci. USA 96(7): 3590-3594.
8. Chili F, Stefani M, Taddei N, Ramponi G, Dobson CM. 2003. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424(6950): 805-808.
9. Collaborative Computational Project N. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50: 760-763.
10. Davis PD, Raffen R, Dul LJ, Vogen MS, Williamson KE, Stevens JF, Argon Y. 2000. Inhibition of amyloid fiber assembly by both BiP and its target peptide. Immunity 13(4): 433-442.
11. Dul JL, Davis DP, Williamson EK, Stevens FJ, Argon Y. 2001. Hsp70 and antifibrillogenic peptides promote degradation and inhibit intracellular aggregation of amyloidogenic light chains. J. Cell. Biol. 152(4): 705-716.
12. Falk RH, Comenzo RL, Skinner M. 1997. The systemic amyloidoses. New Engl. J. Med. 337(13): 898-909.
13. French S, Wilson K. 1978. On the treatment of negative intensities. Acta Crystallogr. A 34: 517-525.
14. Hammarstrom P, Jiang X, Hurshman AR, Powers ET, Kelly JW. 2002. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc. Natl Acad. Sci. USA 99(Suppl. 4): 16427-16432.
15. Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. 2003. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299(5607): 713-716.
16. Harper JD, Lansbury PT. 1997. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. A. Rev. Biochem. 66: 385-407.
17. Hopp TP. 1989. Use of hydrophilicity plotting procedures to identify protein antigenic segments and other interaction sites. Meth. Enzymol. 178: 571-585.
18. Hurle MR, Helms LR, Li L, Chan W, Wetzel R. 1994. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc. Natl Acad. Sci. USA 91(12): 5446-5450.
19. Jiang X, Buxbaum JN, Kelly JW. 2001. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc. Natl Acad. Sci. USA 98(26): 14943-14948.
20. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. 1991. Improved Methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47: 110-119.
21. Khurana R, Gillespie JR, Talapatra A, Minert LJ, Ionescu-Zanetti C, Millett I, Fink AL. 2001. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry 40(12): 3525-3535.
22. Khurana R, Ionescu-Zanetti C, Pope M, Li J, Nielson L, Ramirez-Alvarado M, Regan L, Fink AL, Carter SA. 2003a. A general model for amyloid fibril assembly based on morphological studies using atomic force microscopy. Biophys. J. 85(2): 1135-1144.
23. Khurana R, Souillac PO, Coats AC, Minert L, Ionescu-Zanetti C, Carter SA, Solomon A, Fink AL. 2003b. A model for amyloid fibril formation in immunoglobulin light chains based on comparison of amyloidogenic and benign proteins and specific antibody binding. Amyloid 10(2): 97-109.
24. Kim Y, Wall JS, Meyer J, Murphy C, Randolph TW, Manning MC, Solomon A, Carpenter JF. 2000. Thermodynamic modulation of light chain amyloid fibril formation. J. Biol. Chem. 275(3): 1570-1574.
25. Kim YS, Randolph TW, Manning MC, Stevens FJ, Carpenter JF. 2003. Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation. J. Biol. Chem. 278(12): 10842-10850.
26. Liemann S, Glockshuber R. 1999. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. Biochemistry 38(11): 3258-3267.
27. McCutchen SL, Colon W, Kelly JW. 1993. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry 32(45): 12119-12127.
28. Merlini G, Bellotti V. 2003. Molecular mechanisms of amyloidosis. New Engl. J. Med. 349(6): 583-596.
29. Minor W, Tomchick D, Otwinowski Z. 2000. Strategies for macromolecular synchrotron crystallography. Structure Fold Des. 15;8(5): R105-R110.
30. Murshudov G, Vagin E, Dobson E. 1996. Application of maximum likelihood refinement. The Refinement of Protein structures, Proceedings of Daresbury Study Weekend.
31. Naiki H, Higuchi K, Hosokawa M, Takeda T. 1989. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal. Biochem. 177(2): 244-249.
32. Navaza J. 1994. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A. 50: 157-163.
33. Omtvedt LA, Bailey D, Renouf DV, Davies MJ, Paramonov NA, Haavik S, Husby G, Sletten K, Hounsell EF. 2000. Glycosylation of immunoglobulin light chains associated with amyloidosis. Amyloid 7(4): 227-244.
34. Ozaki S, Abe M, Wolfenbarger D, Weiss DT, Solomon A. 1994. Preferential expression of human I-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenstroms macroglobulinemia. Clin. Immunol. Immunopatho. 71: 183-189.
35. Plaza del Pino IM, Ibarra-Molero B, Sanchez-Ruiz JM. 2000. Lower kinetic limit to protein thermal stability: a proposal regarding protein stability in vivo and its relation with misfolding diseases. Proteins 40(1): 58-70.
36. Pokkuluri PR, Solomon A, Weiss DT, Stevens FJ, Schiffer M. 1999. Tertiary structure of human lambda 6 light chains. Amyloid 6(3): 165-171.
37. Raffen R, Dieckman LJ, Szpunar M, Wunschl C, Pokkuluri PR, Dave P, Wilkins Stevens P, Cai X, Schiffer M, Stevens FJ. 1999. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Protein Sci. 8(3): 509-517.
38. Rajkumar SV, Gertz MA, Kyle RA. 1998. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am. J. Med. 104(3): 232-237.
39. Safar J, Roller PP, Gajdusek DC, Gibbs CJ Jr. 1993. Thermal stability and conformational transitions of scrapie amyloid (prion) protein correlate with infectivity. Protein Sci. 2(12): 2206-2216.
40. Serpell LC. 2000. Alzheimer's amyloid fibrils: structure and assembly. Biochim. Biophys. Acta 1502(1): 16-30.
41. Serpell LC, Fraser PE, Sunde M. 1999. X-ray fiber diffraction of amyloid fibrils. Meth. Enzymol. 309: 526-536.
42. Serpell LC, Sunde M, Benson MD, Tennent GA, Pepys MB, Fraser PE. 2000. The protofilament substructure of amyloid fibrils. J. Mol. Biol. 300(5): 1033-1039.
43. Sipe JD. 1994. Amyloidosis. Crit. Rev. Clin. Lab. Sci. 31(4): 325-354.
44. Solomon A, Weiss DT. 1995. Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis). Amyloid: Int. J. Exp. Clin. Invest. 2: 269-279.
45. Souillac PO, Uversky VN, Millett IS, Khurana R, Doniach S, Fink AL. 2002. Elucidation of the molecular mechanism during the early events in immunoglobulin light chain amyloid fibrillation. Evidence for an off-pathway oligomer at acidic pH. J. Biol. Chem. 277(15): 12666-12679.
46. Souillac PO, Uversky VN, Fink AL. 2003. Structural transformations of oligomeric intermediates in the fibrillation of the immunoglobulin light chain LEN. Biochemistry 42(26): 8094-8104.
47. Stevens FJ. 2000. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 7(3): 200-211.
48. Sunde M, Blake C. 1997. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv. Protein Chem. 50: 123-159.
49. Takano K, Funahashi J, Yutani K. 2001. The stability and folding process of amyloidogenic mutant human lysozymes. Eur. J. Biochem. 268(1): 155-159.
50. Tan SY, Pepys MB, Hawkins PN. 1995. Treatment of amyloidosis. Am. J. Kidney Dis. 26(2): 267-285.
51. Thual C, Bousset L, Komar AA, Walter S, Buchner J, Cullin C, Melki R. 2001. Stability, folding, dimerization, and assembly properties of the yeast prion Ure2p. Biochemistry 40(6): 1764-1773.
52. Wall J, Schell M, Murphy C, Hrncic R, Stevens FJ, Solomon A. 1999. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry 38(42): 14101-14108.
53. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD. 2002. Amyloid fibril protein nomenclature-2002. Amyloid 9(3): 197-200.